Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01OXI
|
|||
| Former ID |
DIB007049
|
|||
| Drug Name |
DTI-015
|
|||
| Synonyms |
Carmustine; carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; BCNU; Injectable carmustine, Direct Therapeutics
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Brain cancer [ICD-11: 2A00] | Approved | [1], [2] | |
| Liver cancer [ICD-11: 2C12; ICD-10: C22] | Approved | [3] | ||
| Company |
Direct Therapeutics Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C5H9Cl2N3O2
|
|||
| Canonical SMILES |
C(CCl)NC(=O)N(CCCl)N=O
|
|||
| InChI |
1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)
|
|||
| InChIKey |
DLGOEMSEDOSKAD-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 154-93-8
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:3423
|
|||
| ADReCS Drug ID | BADD_D00371 | |||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Parabacteroides
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Parabacteroides was increased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Bifidobacterium was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Atopobium
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Atopobium was increased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
|
Studied Microbe: Collinsella
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Collinsella was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eggerthellales | ||||
|
Studied Microbe: Adlercreutzia
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Adlercreutzia was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Citrobacter
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Citrobacter was increased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
|
Studied Microbe: Klebsiella
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Klebsiella was increased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Blautia was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
|
Studied Microbe: Clostridium
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Clostridium was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
|
Studied Microbe: Coprococcus
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Coprococcus was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
|
Studied Microbe: Dorea
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Dorea was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
|
Studied Microbe: Lachnospira
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Lachnospira was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
|
Studied Microbe: Oscillospira
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Oscillospira was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
|
Studied Microbe: Roseburia
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Roseburia was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
|
Studied Microbe: Ruminococcus
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Ruminococcus was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Enterococcus was increased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Tissierellales | ||||
|
Studied Microbe: Anaerococcus
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Anaerococcus was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Veillonellales | ||||
|
Studied Microbe: Megasphaera
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Megasphaera was increased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human Deoxyribonucleic acid (hDNA) | Target Info | Binder | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6800). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 017422. | |||
| REF 3 | Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur J Cancer. 1991;27(12):1658-62. | |||
| REF 4 | Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther. 2015 Sep;42(5):515-28. | |||
| REF 5 | Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome. 2018 May 22;6(1):92. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.